ANALYSIS OF DOXORUBICIN AND DOXORUBICINOL IN DRIED BLOOD SPOT OF BREAST CANCER PATIENTS FOR MONITORING THE CARDIOTOXICITY OF DOXORUBICIN
Objective: This study aimed to analyze doxorubicin and doxorubicinol levels in Dried Blood Spot (DBS) from 25 breast cancer patients who received doxorubicin in their therapeutic regiment.
Methods: DBS samples were extracted by protein precipitation method and analyzed using Ultra Performance Liquid Chromatography tandem Mass Spectrometry (LC-MS/MS), with the Acquity UPLC BEH C18 Waters chromatography column (2.1 x 100 mm x 1.7 μm). The mobile phase consisted of 0.1% acetic acid (eluent A) and acetonitrile (eluent B) with gradient elution; the flow rate was 0.15 ml/min and runtime, 7 min. This method was linear within the concentration range of 10–200 ng/ml for doxorubicin and 4–100 ng/ml for doxorubicinol.
Result: The analysis results showed that doxorubicin levels were in the range of 11.01 ng/ml to 93.75 ng/ml and doxorubicinol was 5.80 ng/ml to 58.57 ng/ml.
Conclusion: Cumulative doses of all patients were in the range of 49.11 mg/m2to 303.70 mg/m2, which have cardiomyopathy incidence rates<4%.
2. Luu AZ, Chowdhury B, Al-Omran M, Teoh H, Hess DA, Verma S. Role of the endothelium in doxorubicin-induced cardiomyopathy. JACC Basic Transl Sci 2018;3:861–70.
3. Lal S, Sandanaraj E, Wong ZW, Ang PCS, Wong NS, Lee EJD, et al. CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients. Cancer Sci 2008;99:2045-54.
4. Schaupp CM, White CC, Merrill GF, Kavanagh TJ. Chemico-biological interactions metabolism of doxorubicin to the cardiotoxic metabolite doxorubicinol is increased in a mouse model of chronic glutathione deficiency: a potential role for carbonyl reductase 3. Chem Biol Interactions 2015;234:154–61.
5. Evans G. A handbook of bioanalysis and drug metabolism. Taylor and Francis; 2004. Available from: https://books.google.co.id/books?id=vKgikgEACAAJ [Last accessed on 15 Nov 2019]
6. Sottani C, Poggi G, Melchiorre F, Montagna B, Minoia C. Simultaneous measurement of doxorubicin and reduced metabolite doxorubicinol by UHPLC–MS/MS in human plasma of HCC patients treated with TACE. J Chromatogr B: Anal Technol Biomed Life Sci 2013;916:71–8.
7. DiFrancesco R, Griggs JJ, Donnelly J, DiCenzo R. Simultaneous analysis of cyclophosphamide, doxorubicin and doxorubicinol by liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B: Anal Technol Biomed Life Sci 2007;852:545–53.
8. Zakaria R, Allen KJ, Koplin JJ, Roche P, Greaves RF. Advantages and challenges of dried blood spot analysis by mass spectrometry across the total testing process. EJIFCC 2016;27:288–317.
9. Pedersen L, Andersen Ranberg K, Hollergaard M, Nybo M. Quantification of multiple elements in dried blood spot samples. Clin Biochem 2017;50:703–9.
10. Food and Drug Administration. Bioanalytical Method Validation Guidance for Industry. US; 2018.
11. European Medicines Agency. Guideline on bioanalytical method validation. EMEA/CHMP/EWP/192217/2009 Rev Corr 2011;44:1–23.
12. Gonzalez Covarrubias V, Zhang J, Kalabus JL, Relling MV, Blanco JG. Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors. Drug Metab Dispos ?2009;37:400–7.
13. Brunton L, Chabner BA, Knollman B. Goodman and gilman’s the pharmacological basis of therapeuticsmcgraw-hill education; 2011. Available from: https://books.google.co.id/ books?id=e_yAOpyyaowC [Last accessed on 15 Nov 2019].
14. Sherwood L. Fundamentals of Human Physiology. Cengage Learning; 2011. Available from: https://books.google. co.id/books?id=qXwIAAAAQBAJ [Last accessed on 15 Nov 2019].
15. Harmita K, Harahap Y, Supandi. Liquid chromatography-tandem mass spectrometry (LC-MS/MS). Jakarta: ISFI Penerbitan; 2019.
This work is licensed under a Creative Commons Attribution 4.0 International License.